Pages that link to "Item:Q1265963"

The following pages link to Optimal Bayesian-feasible dose escalation for cancer phase I trials (Q1265963):

Displaying 33 items.

• Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates (Q419309) (← links)
• Adaptive Bayesian compound designs for dose finding studies (Q434557) (← links)
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
• On the consistency of the continual reassessment method with multiple toxicity constraints (Q499432) (← links)
• The treatment versus experimentation dilemma in dose finding studies (Q538132) (← links)
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach (Q725696) (← links)
• Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
• Continual reassessment and related dose-finding designs (Q903292) (← links)
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293) (← links)
• Approximate dynamic programming and its applications to the design of Phase I cancer trials (Q903295) (← links)
• Convergence properties of sequential Bayesian \(D\)-optimal designs (Q958799) (← links)
• Unifying CRM and EWOC designs for phase I cancer clinical trials (Q1007501) (← links)
• Optimal sequential designs in phase I studies (Q1621308) (← links)
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
• Methodology and application of adaptive and sequential approaches in contemporary clinical trials (Q1929694) (← links)
• Number of patients per cohort and sample size considerations using dose escalation with overdose control (Q1929695) (← links)
• Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
• Optimal designs for dose-escalation trials and individual allocations in cohorts (Q2084331) (← links)
• A causal exposure response function with local adjustment for confounding: estimating health effects of exposure to low levels of ambient fine particulate matter (Q2194470) (← links)
• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors (Q2233150) (← links)
• On optimal designs for clinical trials: an updated review (Q2301225) (← links)
• Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
• Theoretical study of the continual reassessment method (Q2492919) (← links)
• A conversation with Shelemyahu Zacks (Q2503970) (← links)
• Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs (Q3013989) (← links)
• Patient-specific dose finding in phase I clinical trials (Q5036370) (← links)
• (Q5072154) (← links)
• A new design of the continual reassessment method (Q5082671) (← links)
• Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
• Performance Measures in Dose‐Finding Experiments (Q6085864) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages (Q6572291) (← links)